Literature DB >> 26206803

MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis.

Anne Lazareth1, Xiu-Yi Song2, Aurelie Coquin3, Stephanie Harel4, Lionel Karlin4, Karim Belhadj5, Damien Roos-Weil6, Laurent Frenzel7, Jerôme Tamburini8, Margaret Macro9, Sylvie Chevret10, Hervé Avet Loiseau11, Stephane Minvielle12, Jean Paul Fermand1, Jean Soulier3, Jean Christophe Bories2, Bertrand Arnulf13.   

Abstract

Entities:  

Keywords:  MB4 breakpoint; MMSET; heterogeneity; prognostic factor; t(4/14) translocation

Mesh：

Year:  2015        PMID： 26206803      PMCID： PMC4825293          DOI： 10.3324/haematol.2015.127001

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

Authors:  Hervé Avet-Loiseau; Xavier Leleu; Murielle Roussel; Philippe Moreau; Catherine Guerin-Charbonnel; Denis Caillot; Gérald Marit; Lotfi Benboubker; Laurent Voillat; Claire Mathiot; Brigitte Kolb; Margaret Macro; Loïc Campion; Marc Wetterwald; Anne-Marie Stoppa; Cyrille Hulin; Thierry Facon; Michel Attal; Stéphane Minvielle; Jean-Luc Harousseau
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

2.  Clinical and biological features of t(4;14) multiple myeloma: a prospective study.

Authors:  Lionel Karlin; Jean Soulier; Olivia Chandesris; Sylvain Choquet; Karim Belhadj; Margaret Macro; Didier Bouscary; Raphael Porcher; David Ghez; Marion Malphettes; Bouchra Asli; Jean Claude Brouet; Jean Christophe Bories; Olivier Hermine; Jean Paul Fermand; Bertrand Arnulf
Journal:  Leuk Lymphoma       Date:  2011-01-24

3.  Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies.

Authors:  J A Oyer; X Huang; Y Zheng; J Shim; T Ezponda; Z Carpenter; M Allegretta; C I Okot-Kotber; J P Patel; A Melnick; R L Levine; A Ferrando; A D Mackerell; N L Kelleher; J D Licht; R Popovic
Journal:  Leukemia       Date:  2013-07-04       Impact factor: 11.528

4.  Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients.

Authors:  Jonathan J Keats; Christopher A Maxwell; Brian J Taylor; Michael J Hendzel; Marta Chesi; P Leif Bergsagel; Loree M Larratt; Michael J Mant; Tony Reiman; Andrew R Belch; Linda M Pilarski
Journal:  Blood       Date:  2005-01-27       Impact factor: 22.113

5.  The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells.

Authors:  Lucía López-Corral; Norma C Gutiérrez; Maria Belén Vidriales; Maria Victoria Mateos; Ana Rasillo; Ramón García-Sanz; Bruno Paiva; Jesús F San Miguel
Journal:  Clin Cancer Res       Date:  2011-02-16       Impact factor: 12.531

6.  NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.

Authors:  Alex J Kuo; Peggie Cheung; Kaifu Chen; Barry M Zee; Mitomu Kioi; Josh Lauring; Yuanxin Xi; Ben Ho Park; Xiaobing Shi; Benjamin A Garcia; Wei Li; Or Gozani
Journal:  Mol Cell       Date:  2011-11-18       Impact factor: 17.970

7.  Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy.

Authors:  Philippe Moreau; Thierry Facon; Xavier Leleu; Nadine Morineau; Pauline Huyghe; Jean-Luc Harousseau; Régis Bataille; Hervé Avet-Loiseau
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

8.  The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.

Authors:  M Chesi; E Nardini; R S Lim; K D Smith; W M Kuehl; P L Bergsagel
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

9.  In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.

Authors:  Jonathan J Keats; Tony Reiman; Christopher A Maxwell; Brian J Taylor; Loree M Larratt; Michael J Mant; Andrew R Belch; Linda M Pilarski
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

10.  Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia.

Authors:  Jacob D Jaffe; Yan Wang; Ho Man Chan; Jinghui Zhang; Robert Huether; Gregory V Kryukov; Hyo-eun C Bhang; Jordan E Taylor; Min Hu; Nathan P Englund; Feng Yan; Zhaofu Wang; E Robert McDonald; Lei Wei; Jing Ma; John Easton; Zhengtian Yu; Rosalie deBeaumount; Veronica Gibaja; Kavitha Venkatesan; Robert Schlegel; William R Sellers; Nicholas Keen; Jun Liu; Giordano Caponigro; Jordi Barretina; Vesselina G Cooke; Charles Mullighan; Steven A Carr; James R Downing; Levi A Garraway; Frank Stegmeier
Journal:  Nat Genet       Date:  2013-09-29       Impact factor: 38.330
View more
  4 in total

Review 1.  The effect of novel therapies in high-molecular-risk multiple myeloma.

Authors:  Guido Lancman; Douglas Tremblay; Kevin Barley; Bart Barlogie; Hearn Jay Cho; Sundar Jagannath; Deepu Madduri; Erin Moshier; Samir Parekh; Ajai Chari
Journal:  Clin Adv Hematol Oncol       Date:  2017-11

2.  MMSET I acts as an oncoprotein and regulates GLO1 expression in t(4;14) multiple myeloma cells.

Authors:  Zhigang Xie; Jing Yuan Chooi; Sabrina Hui Min Toh; Dongxiao Yang; Nurhidayah Binte Basri; Ying Swan Ho; Wee Joo Chng
Journal:  Leukemia       Date:  2018-11-23       Impact factor: 11.528

Review 3.  Genetic Predictors of Mortality in Patients with Multiple Myeloma.

Authors:  Hamza Hassan; Raphael Szalat
Journal:  Appl Clin Genet       Date:  2021-04-29

4.  MB4-2/MB4-3 transcripts of IGH-MMSET fusion gene in t(4;14)pos multiple myeloma indicate poor prognosis.

Authors:  Feng Li; Yong-Ping Zhai; Ting Lai; Qian Zhao; Hui Zhang; Yu-Mei Tang; Jian Hou
Journal:  Oncotarget       Date:  2017-05-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.